Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Comment
. 2017 May;15(3):281-282.
doi: 10.2450/2017.0285-16. Epub 2017 Mar 2.

The increased demand for plasma-derived factor VIII in Italy between 2011 and 2014 is attributable to treatment of adult patients rather than paediatric or previously unexposed patients with severe haemophilia A

Antonio Coppola  1 , Elena Santagostino  1 , Hamisa J Hassan  1 , Angelo C Molinari  1 , Rita C Santoro  1 , Annarita Tagliaferri  1 , Massimo Morfini  1 , Giovanni Di Minno  1
Affiliations
Comment

The increased demand for plasma-derived factor VIII in Italy between 2011 and 2014 is attributable to treatment of adult patients rather than paediatric or previously unexposed patients with severe haemophilia A

Antonio Coppola et al. Blood Transfus. 2017 May.
No abstract available

PubMed Disclaimer

Conflict of interest statement

Disclosure of conflicts of interest

AC has received fees as an invited speaker or consultant from Baxter, Bayer, NovoNordisk and Octapharma. ES has acted as a paid consultant or invited speaker for Baxter, Bayer, Biogen Idec, Biotest, CSL Behring, Grifols, Kedrion, NovoNordisk, Octapharma, Pfizer, Roche and Sobi, and has received an unrestricted research grant from Pfizer; ACM has received fees as an invited speaker or a member of advisory boards from Bayer, CSL Behring, Kedrion, NovoNordisk, Pfizer and Sobi; RCS has received fees as an invited speaker or member of advisory boards from Baxalta, Bayer, BioVIIIx, Boehringer Ingelheim, Bristol-Myers-Squibb, CSL Behring, Pfizer, Sanofi-Aventis and Sobi; AT has acted as a member of an advisory board or consultant for Baxter, Bayer, CSL Behring, NovoNordisk, Pfizer and Sobi; MM has acted as a paid consultant or invited speaker for Baxter, Bayer, CSL Behring, NovoNordisk, Octapharma and Pfizer, and has received research grants from Baxter, Bayer and Pfizer. GDM has acted as a consultant or ad hoc speaker for Bayer, Boehringer Ingelheim, Biotest, CSL Behring, Eli Lilly, Grifols, NovoNordisk, Pfizer and Sanofi-Aventis. HJH declared no conflicts of interests.

Comment in

Comment on

References

    1. Arcieri R, Calizzani G, Candura F, Mannucci PM. The increased demand for plasma-derived factor VIII in Italy. Blood Transfus. 2017;15:279–80. - PMC - PubMed
    1. Candura F, Lanzoni M, Calizzani G, et al. Rapporti ISTISAN 16/7. Roma: Istituto Superiore di Sanita; 2016. [In Italian.]
    1. Rocino A, Coppola A, Franchini M, et al. Principles of treatment and update of recommendations for management of haemophilia and congenital bleeding disorders in Italy. Blood Transfus. 2014;12:575–98. - PMC - PubMed
    1. Peyvandi F, Mannucci PM, Garagiola I, et al. A randomized trial of factor VIII and neutralizing antibodies in hemophilia A. N Engl J Med. 2016;374:2054–64. - PubMed
    1. Abbonizio F, Giampaolo A, Arcieri R, Hassan HJ Associazione Italiana Centri Emofilia (AICE) Rapporti ISTISAN 16/20. Roma: Istituto Superiore di Sanita; 2016. [In Italian.]